JP MORGAN/CALL/VERTEX PHARMACEUTICALS/520/0.1/19.07.24 | Market Closed - Börse Stuttgart 09:22:56 01/07/2024 BST | ||
| 0.055 EUR | -44.44% |
|
| Current month | -44.44% | ||
| 1 month | -65.62% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 01/07/24 | 0.055 | -44.44% |
| 28/06/24 | 0.099 | -10.00% |
| 27/06/24 | 0.11 | -31.25% |
| 25/06/24 | 0.16 | +33.33% |
| 24/06/24 | 0.12 | -25.00% |
Delayed Quote Börse Stuttgart
Last update July 01, 2024 at 09:22 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | J.P. Morgan |
| WKN | JB96C6 |
| ISIN | DE000JB96C68 |
| Date issued | 08/01/2024 |
| Strike | 520 $ |
| Maturity | 19/07/2024 (18 Days) |
| Parity | 10 : 1 |
| Emission price | 0.73 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.48 € |
|---|---|
| Lowest since issue | 0.036 € |
| Spread | 0.5 € |
| Spread % | 87.72% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
471.2
USD
Average target price
468.3
USD
Spread / Average Target
-0.63%
- Stock Market
- Warrants
- Warrant
